ES399057A1 - Procedimiento para preparar compuestos esteroides que tie- nen propiedades anti-inflamatorias. - Google Patents

Procedimiento para preparar compuestos esteroides que tie- nen propiedades anti-inflamatorias.

Info

Publication number
ES399057A1
ES399057A1 ES399057A ES399057A ES399057A1 ES 399057 A1 ES399057 A1 ES 399057A1 ES 399057 A ES399057 A ES 399057A ES 399057 A ES399057 A ES 399057A ES 399057 A1 ES399057 A1 ES 399057A1
Authority
ES
Spain
Prior art keywords
group
atom
chlorine
17alpha
beta configuration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES399057A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Laboratories Ltd
Original Assignee
Glaxo Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Laboratories Ltd filed Critical Glaxo Laboratories Ltd
Publication of ES399057A1 publication Critical patent/ES399057A1/es
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J3/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Steroid Compounds (AREA)
ES399057A 1971-01-20 1972-01-20 Procedimiento para preparar compuestos esteroides que tie- nen propiedades anti-inflamatorias. Expired ES399057A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB278771A GB1384372A (en) 1971-01-20 1971-01-20 Dereivatives of 17alpha-hydroxyandrost-4-ene-17beta-carboxylic acids

Publications (1)

Publication Number Publication Date
ES399057A1 true ES399057A1 (es) 1974-11-01

Family

ID=9745890

Family Applications (1)

Application Number Title Priority Date Filing Date
ES399057A Expired ES399057A1 (es) 1971-01-20 1972-01-20 Procedimiento para preparar compuestos esteroides que tie- nen propiedades anti-inflamatorias.

Country Status (17)

Country Link
JP (1) JPS5611720B1 (es)
AU (1) AU473868B2 (es)
BE (1) BE778285A (es)
CA (1) CA1003820A (es)
CH (1) CH602786A5 (es)
DE (1) DE2202691A1 (es)
DK (1) DK132894C (es)
ES (1) ES399057A1 (es)
FR (1) FR2122539B1 (es)
GB (1) GB1384372A (es)
HK (1) HK34278A (es)
IE (1) IE36000B1 (es)
IL (1) IL38589A (es)
NL (1) NL172511C (es)
NO (1) NO137321C (es)
SE (1) SE383522B (es)
ZA (1) ZA72401B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1438940A (en) * 1972-07-19 1976-06-09 Glaxo Lab Ltd 17beta-haloalkoxycarbonyl-17alpha-oxysteroids
DE2365102C2 (de) * 1973-12-21 1982-12-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Neue Pregnansäure-Derivate
DE2444618C2 (de) * 1974-09-16 1984-01-19 Schering AG, 1000 Berlin und 4709 Bergkamen Neue Pregnan-21-säure-Derivate
DE2319479C2 (de) * 1973-04-14 1982-10-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen Pregnansäure-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate
GB1514476A (en) * 1974-08-30 1978-06-14 Glaxo Lab Ltd Alkyl and haloalkyl androst-4-ene and androsta-1,4-diene-17beta-carboxylates
SE427276B (sv) * 1975-04-03 1983-03-21 Hoffmann La Roche Forfarande for framstellning av d-homosteroider
CH628355A5 (de) * 1976-02-24 1982-02-26 Ciba Geigy Ag Verfahren zur herstellung neuer androstadien-17beta-carbonsaeuren und ihrer ester und salze.
IT1114534B (it) * 1978-02-08 1986-01-27 Glaxo Group Ltd Steroide anti-infiammatorio della serie dell'androstano composizioni che lo contengono e procedimento per produrlo
CA1138857A (en) * 1979-01-24 1983-01-04 Leo Alig D-homosteroids
SE449106B (sv) * 1980-07-10 1987-04-06 Otsuka Pharma Co Ltd Steroid med anti-inflammatorisk verkan samt komposition innehallande denna
JPS59139315A (ja) * 1983-01-31 1984-08-10 Taisho Pharmaceut Co Ltd クリ−ム剤
US4607028A (en) * 1983-08-18 1986-08-19 Ciba-Geigy Corporation Novel carboxylic acid esters
US5981517A (en) * 1996-05-09 1999-11-09 Soft Drugs, Inc. Androstene derivatives
GB0015876D0 (en) * 2000-06-28 2000-08-23 Novartis Ag Organic compounds
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
AR032361A1 (es) 2000-08-05 2003-11-05 Glaxo Group Ltd Derivados de androstano y sales y solvatos de los mismos, su uso para la fabricacion de medicamentos, composiciones farmaceuticas que comprenden tales compuestos, proceso para la preparacion de dichos compuestos, e intermediarios utiles en la preparacion de tales compuestos
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
JP4446661B2 (ja) 2001-04-30 2010-04-07 グラクソ グループ リミテッド 抗炎症性の、17α位に環状エステル基を有するアンドロスタンの17β−カルボチオ酸エステル誘導体
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
CA2558941C (en) 2003-06-19 2012-05-15 Nicholas S. Bodor Enhancement of activity and/or duration of action of selected anti-inflammatory steroids
DE602004025002D1 (de) 2003-06-19 2010-02-25 Nicholas S Bodor Steigerung der aktivität und/oder der wirkungsdauer weicher steroide mit anti-entzündungswirkung für topische oder lokale verabreichung
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
ATE517908T1 (de) 2005-01-10 2011-08-15 Glaxo Group Ltd Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände
US7691811B2 (en) 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
US7687484B2 (en) 2006-05-25 2010-03-30 Bodor Nicholas S Transporter enhanced corticosteroid activity
DE102010029877A1 (de) 2010-06-09 2011-12-15 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Herstellung von 1,4-Pregna-diensäure-Derivaten
DE102010029875A1 (de) 2010-06-09 2011-12-15 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Herstellung von 1,4-Pregna-diensäure-Derivaten
US8835410B2 (en) 2011-05-10 2014-09-16 Bodor Laboratories, Inc. Treatment of eyelid dermatitis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3636010A (en) * 1968-12-23 1972-01-18 Ciba Geigy Corp Esters of steroid-17-carboxylic acids

Also Published As

Publication number Publication date
AU3811072A (en) 1973-07-26
DK132894C (da) 1976-07-26
CH602786A5 (es) 1978-08-15
DK132894B (da) 1976-02-23
NL7200818A (es) 1972-07-24
BE778285A (fr) 1972-07-20
IE36000L (en) 1972-07-20
SE383522B (sv) 1976-03-15
CA1003820A (en) 1977-01-18
DE2202691A1 (de) 1972-08-03
NO137321C (no) 1978-02-08
ZA72401B (en) 1973-09-26
GB1384372A (en) 1975-02-19
IE36000B1 (en) 1976-07-21
AU473868B2 (en) 1976-07-08
HK34278A (en) 1978-07-07
IL38589A0 (en) 1972-03-28
FR2122539B1 (es) 1975-11-28
NL172511C (nl) 1983-09-16
FR2122539A1 (es) 1972-09-01
NL172511B (nl) 1983-04-18
JPS5611720B1 (es) 1981-03-16
IL38589A (en) 1976-06-30
NO137321B (no) 1977-10-31

Similar Documents

Publication Publication Date Title
ES399057A1 (es) Procedimiento para preparar compuestos esteroides que tie- nen propiedades anti-inflamatorias.
ES417012A2 (es) Mejoras introducidas en el objeto de la patente principal, num. 399.057.
ES438946A2 (es) Procedimiento de prreparacion de esteres cicloalquil alqui- licos de acidos que el esqueleto de eburnano
ES425626A1 (es) Un procedimiento para preparar compuestos de acil-xilidida.
ES451466A1 (es) Procedimiento para la preparacion de nuevos derivados de 5- tiazol-metanoamina.
ES392784A1 (es) Procedimiento para la preparacion de 3 beta - hidroxi - 5 alfa - cardenolidas y bufadienolidas.
ES394504A1 (es) Un procedimiento para la preparacion de compuestos trici- clicos.
ES442051A1 (es) Procedimiento para preparar aminoglicosidos de 2-deoxies- treptamina.
ES385197A1 (es) Un procedimiento para la preparacion de compuestos ciclo- pentanicos.
ES441775A1 (es) Procedimiento para preparar colorantes antraquinonicos solu-bles en agua.
ES400056A1 (es) Procedimiento para la preparacion de nuevos 16 alfa, 16 al-fa-metilenesteroides.
ES392355A1 (es) Un procedimiento para la preparacion de derivados de d-ho- moimida.
GB910913A (en) Pyran derivatives and process for their manufacture
ES400623A1 (es) Procedimiento para la preparacion de una composicion farma-ceutica.
ES438725A1 (es) Un procedimiento de preparacion de derivados sustituidos del acido prostanoico.
ES390754A1 (es) Procedimiento para la preparacion de nuevos derivados de tiazoloquinolina.
ES402640A1 (es) Procedimiento para la preparacion de nuevos esteres alcohi-licos de acido tiolcarbamidico basicamente sustituidos.
ES325262A1 (es) Procedimiento para la produccion de esteroides.
ES437041A1 (es) Un procedimiento para preparar derivados de 1-ftalazona.
ES376501A1 (es) Procedimiento de preparacion de nuevos acetales ciclicos derivados del pregnano.
ES396701A1 (es) Procedimiento de preparacion de nuevos derivados del acido tiofeno-acetico.
GB845586A (en) Improvements in or relating to indoline compounds
GB1023719A (en) Substituted 19-norandrosta-5(10),9(11)-dienes and method of preparing same
ES303113A1 (es) Procedimiento para preparar cetonas esteroides y sus derivados.
ES428016A1 (es) Un procedimiento para preparar nuevos aminoacidos.

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19840222